Trial
NCT00500500
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Alzheimer Disease
Intervention
EGb 761® (Tanakan®)
Why stopped
Inability to recruit sufficient number of patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-26